New pill shows promise for stubborn depression
NCT ID NCT05066672
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new drug called NV-5138 in 250 adults with treatment-resistant depression (depression that hasn't improved with standard treatments). Participants took either the drug or a placebo for several weeks. The main goal was to see if the drug reduces depression symptoms better than placebo, measured by a standard depression scale.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- NV-5138 (also called SPN820), a drug that boosts a cell signaling pathway
- What this could lead to
- If it works, this could offer a new option for people with depression that hasn't responded to other treatments.
- What could go wrong
- This is a Phase 2 trial, so it's still early. The drug may not work better than placebo, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TREATMENT RESISTANT DEPRESSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Northwest Clinical Research Center, Inc.
Bellevue, Washington, 98007, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Brain 'Radio' tunes into Depression's neural signals
- Magic mushroom compound tested for dual relief of chronic pain and depression
- Ketamine plus talk therapy shows promise for stubborn depression
- Brain zaps guided by scans: a new hope for untreatable depression?
- Magic mushroom compound may offer new hope for stubborn depression
- Can a blood test predict who will respond to ketamine for depression?